Epirubicin, paclitaxel and CMF as adjuvant treatment in node positive patients with operable breast cancer. Safety analysis of a randomized phase III study comparing two dose-dense sequential regimens.

被引：0
|
作者：
Fountzilas, G [1 ]
Gogas, H [1 ]
Papadimitriou, CH [1 ]
Kalofonos, HP [1 ]
Tsavdaridis, D [1 ]
Christodoulou, CH [1 ]
Briasoulis, E [1 ]
Bafaloukos, D [1 ]
Karina, M [1 ]
Markopoulos, CH [1 ]
Pectasides, D [1 ]
Karapanagiotis, K [1 ]
Papakostas, P [1 ]
Aravantinos, G [1 ]
Kosmidis, P [1 ]
Stathopoulos, GP [1 ]
Dimopoulos, AM [1 ]
机构：
[1] Data Off, Athens, Greece
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S108 / S108
页数：1
相关论文
共 50 条
  • [1] Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in patients with operable breast cancer and ≥10 positive axillary nodes
    Fountzilas, G
    Dimopoulos, M
    Papadimitriou, C
    Aravantinos, G
    Briassoulis, E
    Bafaloukos, D
    Papakostas, P
    Pavlidis, N
    Skarlos, D
    ANNALS OF ONCOLOGY, 1998, 9 : 179 - 179
  • [2] Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer
    George Fountzilas
    Dimitrios Pectasides
    Christos Christodoulou
    Eleni Timotheadou
    Theofanis Economopoulos
    Pavlos Papakostas
    Christos Papadimitriou
    Helen Gogas
    Ioannis Efstratiou
    Dimosthenis Skarlos
    Medical Oncology, 2006, 23 : 479 - 488
  • [3] Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer
    Fountzilas, George
    Pectasides, Dimitrios
    Christodoulou, Christos
    Timotheadou, Eleni
    Economopoulos, Theofanis
    Papakostas, Pavlos
    Papadimitriou, Christos
    Gogas, Helen
    Efstratiou, Ioannis
    Skarlos, Dimosthenis
    MEDICAL ONCOLOGY, 2006, 23 (04) : 479 - 488
  • [4] Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
    Fountzilas, G
    Papadimitriou, C
    Aravantinos, G
    Nicolaides, C
    Stathopoulos, G
    Bafaloukos, D
    Kalofonos, H
    Ekonomopoulos, T
    Skarlos, D
    Pavlidis, N
    Dimopoulos, AM
    ONCOLOGY, 2001, 60 (03) : 214 - 220
  • [5] DOSE-DENSE SEQUENTIAL ADJUVANT CHEMOTHERAPY WITH EPIRUBICIN, PACLITAXEL AND CMF VERSUS EPIRUBICIN, CMF AND WEEKLY DOCETAXEL OR PACLITAXEL FOLLOWED BY TRASTUZUMAB FOR ONE YEAR IN PATIENTS WITH EARLY BREAST CANCER
    Fountzilas, G.
    Gogas, H.
    Pavlidis, N.
    Eleftheraki, A.
    Skarlos, D.
    Koutras, A.
    Timotheadou, E.
    Papandreou, C.
    Pectasides, D.
    Dimopoulos, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 95 - 95
  • [6] Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group
    Fountzilas, G
    Skarlos, D
    Dafni, U
    Gogas, H
    Briasoulis, E
    Pectasides, D
    Papadimitriou, C
    Markopoulos, C
    Polychronis, A
    Kalofonos, HP
    Siafaka, V
    Kosmidis, P
    Timotheadou, E
    Tsavdaridis, D
    Bafaloukos, D
    Papakostas, P
    Razis, E
    Makrantonakis, P
    Aravantinos, G
    Christodoulou, C
    Dimopoulos, AM
    ANNALS OF ONCOLOGY, 2005, 16 (11) : 1762 - 1771
  • [7] Dose-Dense Docetaxel versus Weekly Paclitaxel following Dose-Dense Epirubicin and Cyclophosphamide as Adjuvant Chemotherapy in Node-Positive Breast Cancer Patients: A Retrospective Cohort Analysis
    Khoshroo, Sara
    Sandoughdaran, Saleh
    Sabetrasekh, Parisa
    Hajian, Parastoo
    Bikdeli, Pegah
    Sabetrasekh, Parto
    Nasrollahi, Fatemeh
    Yeganeh, Ladan Mohammadi
    Naeini, Sepideh Jafari
    Mirzaei, Hamid Reza
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2021, 2021
  • [8] Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel (taxol®) and CMF (E-T-CMF) vs epirubicin and CMF (E-CMF) in high-risk patients with breast cancer (BC).
    Fountzilas, G
    Papadimitriou, C
    Briassoulis, E
    Kalofonos, HP
    Christodoulou, C
    Razis, E
    Gogas, H
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 249 - 249
  • [9] Sequential dose-dense epirubicin/paclitaxel followed by dose-dense CMF for resectable high-risk breast cancer patients - first toxicity evaluation of a randomized multicenter trial.
    Kuemmel, S
    Krocker, J
    Breitbach, GP
    Blohmer, JU
    Kohls, A
    Morack, G
    Koehler, U
    Schlosser, H
    Elling, D
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 249 - 249
  • [10] Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00
    Fountzilas, G.
    Dafni, U.
    Gogas, H.
    Linardou, H.
    Kalofonos, H. P.
    Briasoulis, E.
    Pectasides, D.
    Samantas, E.
    Bafaloukos, D.
    Stathopoulos, G. P.
    Karina, M.
    Papadimitriou, C.
    Skarlos, D.
    Pisanidis, N.
    Papakostas, P.
    Markopoulos, C.
    Tzorakoeleftherakis, E.
    Dimitrakakis, K.
    Makrantonakis, P.
    Xiros, N.
    Polichronis, A.
    Varthalitis, I.
    Karanikiotis, C.
    Dimopoulos, A. M.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 853 - 860
12345